Launch of Insilico’s Phase II Program Highlights Generative AI Momentum

Thus, nearly a decade later, AI technology is just beginning to hit primetime in drug development, with Insilico’s Phase II as one reflection of that success. “So far, only a few AI-discovered drugs have entered clinical trials [and] most of them are in Phase I clinical trials,” said Chris Meier, managing director and partner at the Boston Consulting Group. Going forward, we are likely to see other AI-discovered drugs entering clinical trials, including Phase II . Pictured: Insilico lab space/Courtesy of Insilico MedicineThe Evolving AI SpaceInsilico is not alone in developing AI technologies that could support drug development. Drug target discovery is usually done in academia and moved into drug development after 10 to 15 years of research around the target, she explained.